News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

New Research Finds Severity of COVID-19 Does Not Differ According to Trimester

Society for Maternal-Fetal Medicine

Research shows that pregnant people who contract COVID-19 are at increased risk of severe complications, including hospitalization, ventilation, and death, compared to pregnant people without COVID-19. However, little is known about how the timing of COVID-19 infection during pregnancy might impact a pregnant person’s risk of developing severe symptoms. In a new study to be presented today at the Society for Maternal-Fetal Medicine’s (SMFM) annual meeting, The Pregnancy Meeting™, which is being held virtually, researchers will unveil findings that suggest that the severity of COVID-19 does not differ by trimester. “Regardless of what trimester they are in, pregnant people are at risk of developing severe COVID illness,” said one of the study’s authors, Rachel Schell, MD, a maternal-fetal medicine fellow at the University of Texas Southwestern Medical Center in Dallas. Researchers identified a group of pregnant people at a single urban hospital in Dallas, Parkland Hospital, and followed the progression of their COVID-19 symptoms. From March 18, 2020 to May 31, 2021, 1,092 pregnant people were diagnosed with COVID-19. Sixty-seven people (6 percent) were diagnosed in the first trimester, 309 (28 percent) in the second trimester, and 716 (66 percent) in the third trimester. There were no significant demographic differences between the groups. Across all trimesters, 993 out of 1092 people (90.9 percent) were either asymptomatic or had mild COVID-19 symptoms, and 35 out of 345 people (10.1 percent) who were initially asymptomatic developed moderate, severe, or critical symptoms. Among pregnant patients who were initially asymptomatic or had mild symptoms in any trimester, 5 percent developed moderate, severe, or critical illness. “This research is helpful for us in counseling patients who test positive for COVID,” said another one of the study’s authors, Emily Adhikari, MD, a maternal-fetal medicine subspecialist at the University of Texas Southwestern Medical Center and medical director of perinatal infectious diseases at Parkland Hospital. “There is no reason to be hesitant to get vaccinated because you are early in your pregnancy. You’re still at risk of getting really sick from COVID in your first trimester.” Researchers are in the process of expanding their research to look at whether there are significant differences or changes in COVID severity by trimester due to the Delta variant. SMFM, the Centers for Disease Control and Prevention (CDC), and the American College of Obstetricians and Gynecologists recommend all pregnant people get vaccinated against COVID-19, noting that the vaccines are safe and effective. Vaccination rates among pregnant people continue to remain low despite evidence showing vaccines can help to prevent severe illness during pregnancy. The latest figures from the CDC show that fewer than 36 percent of pregnant people are vaccinated; vaccination rates are even lower among pregnant people who are Black and Hispanic. The abstract has been published in the January 2022 supplement of the American Journal of Obstetrics and Gynecology (AJOG ) and can be accessed at no cost on the AJOG website. To view the presentation of this abstract or other Pregnancy Meeting™ abstracts and events, visit the SMFM website or contact Karen Addis at karen@addispr.com or 301-787-2394. ### The Society for Maternal-Fetal Medicine (SMFM), founded in 1977, is the medical professional society for obstetricians who have additional training in high-risk, complicated pregnancies. SMFM represents more than 5,000 members who care for high-risk pregnant people and provides education, promotes research, and engages in advocacy to reduce disparities and optimize the health of high-risk pregnant people and their families. SMFM and its members are dedicated to optimizing maternal and fetal outcomes and assuring medically appropriate treatment options are available to all patients. For more information, visit SMFM.org and connect with the organization on Facebook and Twitter. For the latest 2022 Annual Meeting news and updates, follow the hashtag #smfm22. EMBARGOED FOR RELEASE: Feb. 3, 2022 9:00 a.m. EST Contact Details Karen Addis +1 301-787-2394 KAREN@ADDISPR.COM Company Website https://www.smfm.org/

February 03, 2022 09:00 AM Eastern Standard Time

Article thumbnail News Release

Reaxys to enhance chemistry patents with patent provenance for greater competitive intelligence insights

Elsevier

Elsevier, a global leader in research publishing and information analytics, is pleased to announce its market leading position in chemistry patent coverage and the extension of its collaboration with LexisNexis® PatentSight®. In March 2021, Elsevier launched its initiative to strengthen the existing patent coverage in Reaxys ®. The content expansion resulted in a 15-fold increase in patent coverage and ensures pharma and chemical companies and their researchers do not miss key competitive intelligence insights. The number of discoverable patents in Reaxys now exceeds 30 million, and the Reaxys-PatentSight collaboration will further enhance content with the patents’ ownership information. These insights will enable companies to better understand competitors’ IP strategies, identify innovative players in a field and confidently assess the commercial viability of their projects. Marco Richter, Global Head of Product, LexisNexis Intellectual Property Solutions, said: “Competition is intense in R&D: With an increasingly diverse landscape of players in the pharmaceutical industry — from niche start-ups to emerging biotech companies, to academic research. To strengthen drug discovery capabilities and shorten development cycle, pharma companies often acquire specialized biotech companies or in-license drug candidates active in preclinical and clinical phases. “Keeping up with the latest information about competitor IP activity and new research is a business-critical challenge. We are pleased to be continuing our collaboration with Elsevier to provide companies with more extensive information on IP history and understand that getting new drugs to market is a resource-intensive process for researchers and know our content can help accelerate this.” The Reaxys updates will enhance competitive intelligence by distinguishing “current patent assignee” and “original patent assignee” to track ownership over time, demonstrating which companies are most prominent in a particular field. Easy-to-use search filters will allow users to sort between inventors and current patent holders. Further enhancements to the patent assignee ontology that unify different common and legal names for corporations will be released in 2022. This allows companies to avoid blind spots and stay on top of emerging competitors when assessing the competitive landscape for a technology. Dr. Ivan Krstic, Head of Chemistry Solutions at Elsevier added: “Reaxys users want to clearly view current and past patent holders. These upgrades are in response to their feedback, and underlines our commitment to addressing user needs and responding in a timely manner with significant enhancements to the content and user experience. Because of this virtuous cycle, Reaxys has become the patent discovery space for chemists in pharma and chemical companies. “This work underpins our vision to make Reaxys the most comprehensive, innovative and authoritative chemistry research information system that supports chemistry workflows and use cases, enabling the digital transformation that organizations need to achieve to help drive better research outcomes.” To find out more about the collaboration and patent coverage in Reaxys, visit the Reaxys website. --- About LexisNexis Legal & Professional LexisNexis® Legal & Professional is a leading global provider of legal, regulatory and business information and analytics that help customers increase productivity, improve decision-making and outcomes, and advance the rule of law around the world. As a digital pioneer, the company was the first to bring legal and business information online with its Lexis ® and Nexis ® services. LexisNexis Legal & Professional, which serves customers in more than 150 countries with 10,600 employees worldwide, is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. About LexisNexis Intellectual Property LexisNexis Intellectual Property brings clarity to innovation for businesses worldwide. We enable innovators to accomplish more by helping them make informed decisions, be more productive, comply with regulations and ultimately achieve a competitive advantage for their business. Our suite of workflow and analytics solutions (LexisNexis ® IP Data Direct, LexisNexis PatentAdvisor ®, LexisNexis PatentOptimizer ®, LexisNexis ® PatentSight ® and LexisNexis TotalPatent One ® ) enables companies to be more efficient and effective at bringing meaningful innovations to our world. We are proud to directly support and serve these innovators in their endeavors to better humankind. About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders. Elsevier employs 8,100 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,500+ digitized journals, including The Lancet and Cell; our 40,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier and LexisNexis are part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. Contact Details David Tucker Elsevier Communications, UK d.tucker@elsevier.com Company Website https://www.elsevier.com/

February 02, 2022 09:00 AM Eastern Standard Time

Article thumbnail News Release

G Medical Innovations Holdings Ltd Announces $12 Million Private Placement

G Medical Innovations Holdings

G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) (the "Company"), a telehealth, medical device, and remote patient monitoring company providing clinical-grade solutions for consumers, medical professionals, and healthcare institutions, today announced it has entered into a securities purchase agreement with a single institutional investor to issue, in a private placement, 2,400,000 ordinary shares (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of 2,400,000 ordinary shares, at a purchase price of $5.00 per ordinary share (or pre-funded warrant) and associated warrant, for expected gross proceeds to the Company of approximately $12 million, before deducting placement agent fees and other offering expenses payable by the Company. The warrants will have an exercise price of $5.00 per ordinary share, will be exercisable immediately upon issuance, and will have a term of five years from the date of issuance. The closing of the private placement is expected to occur on or about February 2, 2022 subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the private placement for partial repayment of existing debt and working capital purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent for the private placement. The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Under an agreement with the investors, the Company agreed to file a registration statement with the Securities and Exchange Commission (the "SEC") covering the resale of the ordinary shares to be issued to the investors (including the ordinary shares issuable upon the exercise of the warrants) no later than 15 days after the closing and to use commercially reasonable efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event no later than 60 days in the event of a "full review" by the SEC. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About G Medical Innovations G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease and diabetes. The Company’s current product lines consist of its Prizma medical device (or Prizma), a clinical grade device that can transform almost any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous, and real time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services. Visit https://gmedinnovations.com/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, G Medical is using forward-looking statements when it discusses the closing of the private placement and the expected use of proceeds. Because such statements deal with future events and are based on G Medical’s current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of G Medical could differ materially from those described in or implied by the statements in this press release. The forward looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in G Medical’s prospectus filed pursuant to Rule 424(b)(4), filed with the Securities and Exchange Commission (“SEC”) on June 28, 2021, and in any subsequent filings with the SEC. Except as otherwise required by law, the companies undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. G Medical and McDade Products are not responsible for the contents of third-party websites. INVESTOR RELATIONS CONTACT: G Medical Innovations Kobi Ben-Efraim, CFO +972 8-958-4777 service@gmedinnovations.com Contact Details Kobi Ben-Efraim, CFO +972 8-958-4777 service@gmedinnovations.com Company Website https://gmedinnovations.com/

January 31, 2022 07:00 AM Eastern Standard Time

Article thumbnail News Release

BitX Funding Triumphs With Record 2021 Results

BitX Funding

Fairfield, CT., January 24, 2022— BitX Funding, one of the most prominent alternative lenders in Southern Connecticut, announced a banner year for growth in 2021. Overall, revenue went up 10%, new users increased by 70%, impressions went up 300%, and business applications came in at a rate of 1,275% more than the previous year. Out of all the loans that BitX sold, Startup loans had the highest increase. “Our economy saw solid growth in small business lending and the startup loan category lead the way due to the great resignation”, said Todd Rowe, president of BitX Funding. “We continue to grow BitX revenue with support from internal sales, record marketing results, CT Innovations mentor support, and our raving fans. Our 2022 goals are to continue to build out our lending platform, grow our lender base, obtain our own lending facility, and drive client growth. Our goals are to increase revenue by 160%, have a 133% increase in units sold, and a loan amount increase of 200% in 2022.” Rowe continues to promote his company as a marketplace for small business loans, especially with young entrepreneurs. With one click, you can get a response to your loan request within 24 hours. That makes BitX Funding a partner you can trust in 2022. BitX Funding is an omnichannel marketplace for alternative small business loans and business insurance. BitX connects their clients with the right loan and lender from SBA 7a, start-up loans, short-term loans, mid-term loans to merchant cash advances and business lines of credit. BitX is where lenders compete for your business. Our top-rated lenders focus on real-life business data and cash flow, which means you can qualify for small business loans even if your credit score isn’t perfect. We care about small business and it’s our mission to secure the right funding when you need alternative small business loans within our small business loan marketplace. Contact Details BitX Funding Todd Rowe +1 203-763-1430 info@bitxfunding.com Company Website https://www.bitxfunding.com

January 27, 2022 01:05 PM Eastern Standard Time

Article thumbnail News Release

2021 In Numbers: Mass. Cannabis Industry Testing Statistics

MCR Labs

Following another year of unpredictability, change, and challenges for the Massachusetts cannabis industry, MCR Labs is releasing data that may provide insight into the industry’s continued development. Here are MCR Labs’ most notable stats from Jan. 1, 2021 to Jan. 2, 2022: The Lab saw a 19% increase in samples submitted for testing, in comparison to 2020’s 38% increase. While flower sample submissions decreased by 8%, concentrate and vape submissions grew by 22%. The decrease in flower samples can be reasonably attributed to a regulatory change in batch size enacted in March. Solventless extract sample submission increased by 85%, and can most likely be attributed to the rising popularity of Hash Rosin. Hash Rosin submissions increased by 700%. Samples submitted to MCR in 2021 had a 92.3% pass rate for safety screens, up from 91.2% in 2020. For concentrate and vape samples, the pass rate decreased from 93.5% in 2020 to 91.8% in 2021, which can be attributed mostly to an increase in residual solvent failures. “As more and more facilities come online and employ hydrocarbon extraction techniques, we expect failures to remain the same or increase due to the extremely low regulatory limits,” said Jonathan Wani, Vice President of Business Development at MCR Labs. MCR Labs is licensed as an independent testing laboratory in both the Medical and Adult Use Marijuana programs, both overseen by the Massachusetts Cannabis Control Commission (CCC). The statistics provided here account for product samples submitted for compliance testing by cultivators and product manufacturers from the medical and adult-use programs, as well as home growers, patients, researchers, or curious consumers. About MCR Labs: MCR Labs is one of the longest operational cannabis testing laboratories on the East coast with facilities operating in several legal cannabis markets. We are ISO/IEC 17025:2017 accredited providers of analytical cannabis product testing and R&D services committed to assisting licensed marijuana establishments, patients, researchers, entrepreneurs, and advocates. Our team of chemists and pharmaceutical scientists are dedicated to advancing public health and safety through leading-edge chemical analysis of cannabis products and offering unparalleled guidance and support for partners, regulators, and the communities we serve. For more information visit http://mcrlabs.com. Contact Details MCR Labs Alexandra Gomes +1 508-782-9772 alexandra@mcrlabs.com Company Website http://mcrlabs.com

January 27, 2022 09:00 AM Eastern Standard Time

Article thumbnail News Release

2022 HIGH SCHOOL STUDENT WELLNESS AND TUTORING PLATFORM LAUNCHES AMID PANDEMIC: PROVIDES MUCH NEEDED STRESS REDUCTION, LEARNING STRATEGIES, AND LIFE SKILLS

Holistic Learning

Holistic Learning, founded by neuroscience, physiology and meditation experts Eli Marx-Kahn and Kush Patel, announces the launch of its platform on a mission to “help create a generation of purposeful, confident, and happy young people who are ready to take on the many issues our world faces. By integrating services in multiple domains – academics, wellness, and career development – we aim to help students find their unique paths in life.” The easy and fun to use platform incorporates timely and critical touchpoints for high school students: 1-on-1 tutoring, wellness & meditation courses, learning strategies, college counseling, career development, and life skills. Parents and educators see it as a valuable supplement providing their students with a number of individualized, self-select tools such as breathing exercises to reduce anxiety, STEM, English and writing tutoring, college application advice, and career seminars with professionals from dozens of fields. “We know that students who are healthy, happy, and stress-free are much more receptive to new knowledge. Holistic Learning equips them with the skills they need to manage their many obligations while prioritizing their own well-being,” states Co-Founder and Chief Wellness Officer Eli Marx-Kahn. Holistic Learning comes at a crucial time in education amid continued covid disruptions, isolation and uncertainty. According to “Education in the Pandemic, The Disparate Impacts of COVID-19 on America’s Student”: Emerging evidence shows that the pandemic has negatively affected academic growth, widening pre-existing disparities. In core subjects like math and reading, there are worrisome signs that in some grades students might be falling even further behind pre-pandemic expectations. Further, “The Mental Health of High School Students During the COVID-19 Pandemic” report states: “The American Psychological Association (APA) reports 81% of Gen Z teens (ages 13–17) have experienced more intense stress during the COVID-19 pandemic. Exercise time helps reduce mental health degradation (β3 = -0.153, p = 0.037). Many other factors such as gender, homework time, school time, pre-existing mental health issues, and therapy did not have a significant influence on mental health degradation. Analysis of freeform feedback identified the following three recurring themes: increased stress due homework (13.2%), social isolation or lack of social interactions (8.5%), and lack of support for mental wellbeing (12.3%)." "I am very interested in how the brain works and am passionate about using my knowledge of neuroscience to make studying more fun and manageable for students at every point in their education,” shares Kush Patel, Co-Founder and Chief Learning Officer at Holistic Learning. “Throughout my college years, I helped hundreds of students achieve their academic aspirations through my role as a tutor, peer mentor to students with disabilities, study group leader, and learning strategist. I enjoy creating learning strategy content for students as well as designing a holistic tutoring curriculum to ensure that true and meaningful understanding is achieved." Based on frequency of tutoring desired, tiered subscriptions are available at www.holisticlearning.co, and are priced well below standalone tutoring and counseling programs. Sliding scale scholarship opportunities are available for low income families, by inquiring at info@holisticlearning.co. “Holistic Learning is committed to accessibility and equality of access,” states Marx-Kahn. “It was created as an online space designed to meet the needs that high school alone cannot meet, to help students grow, and to help them visualize their path towards a meaningful and fulfilling future. The Pandemic has made the need for a service like Holistic Learning greater than ever.” ### Holistic Learning is an online learning platform designed to help high school students achieve academic success as well as personal and professional growth. It integrates a range of timely and critical services including 1-on-1 tutoring, learning strategies, meditation & wellness courses, college counseling, life skills, and career seminars. Parents and educators see it as a valuable supplement providing their students with the tools to live healthy, happy, and stress-free lives. www.holisticlearning.co Contact Details AnnMarie Fauske +1 630-880-3485 outreach@holisticlearning.co

January 25, 2022 09:00 AM Central Standard Time

Video Image
Article thumbnail News Release

G Medical Innovations Joins Forces with Serology Covid Testing to Support Safer Classroom Learning in California School Districts Amid Omicron Variant Surge

G Medical Innovations Holdings

G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) (“G Medical” or the "Company"), a Telehealth, medical device, and remote patient monitoring company providing clinical-grade solutions for consumers, medical professionals, and healthcare institutions, today announced it has formed an agreement with Serology Covid Testing to provide zero-cost COVID-19 testing to students, families, and school employees across the State of California. G Medical’s wholly owned subsidiary, G Medical Tests and Services, Inc., will provide end-to-end testing services including setup; certified medical staff; testing kits, supplies and necessary personal protective equipment; and an online patient portal to easily administer tests and provide digital certified lab results. "It's an honor for us to partner with Serology Covid Testing and collaborate with educators and public health officials across the State of California to help keep children and their families safe," said Dr. Yacov Geva, President and CEO of G Medical. "Testing programs like these give schools the freedom and flexibility they need to halt transmission chains and minimize disturbance to all of the vital activities that take place in school communities daily." As phase one of the agreement, the co-branded testing venture includes contracts with multiple private and public institutions enabling more than 5,000 students (not including families and faculty) to be tested weekly. On average, G Medical expects to collect an average of $197.88 per patient encounter, which could amount to more than $1,000,000 in gross revenue per week. The agreement stems from a shared commitment to "keeping schools open" by assisting in the recovery of the U.S. teaching market, reducing educational staff turnover, and assisting in the reversal of the pandemic's disproportionate impact on the education-sector workforce. As the Omicron variant continues to escalate, California school systems are facing teacher shortages, lack of rapid testing options, and the daunting task of keeping schools open for its students statewide. "We are thrilled to establish this long-term partnership with G Medical. This relationship is especially meaningful to us because our testing services are now endorsed by a pioneering healthcare company," said Caroline Grotewiel, CEO of Serology Covid Testing. "As a result of our collaborative efforts, we can help students, educators, and their families have more peace of mind, and our classrooms will be more conducive to in-person learning.” Communities across the country have turned to COVID-19 testing to monitor the virus as more vaccine trials for people under the age of 16 are just getting started, and efforts to track and mitigate viral spread remain critical. Together, the companies will offer on-site Rapid Antigen Testing with confirmatory PCR tests, as recommended by the Centers for Disease Control (CDC). “Hundreds of students and staff have tested positive for the virus since schools reopened after the holidays, forcing some districts to switch to remote learning just days after reopening,” added Andrew Benavente, Vice President of Serology Covid Testing. “By implementing these free testing services at their doorstep, we can empower students and teaching staff to return to school as quickly and safely as possible after a potential exposure.” "G Medical has long been at the forefront of medical devices, offering remote patient monitoring tools to help keep patients healthy. We're excited to expand our portfolio to offer COVID-19 testing options that help to detect the virus early and enable individuals, businesses, and schools to take appropriate action to prevent further spread in the community," concluded Geva. If you are interested in offering your school free on-site COVID-19 testing services, please contact Andrew Benavente at Serology Covid Testing; +1 310-747-5473; Andrew.m@Serology-Testing.com. About Serology Covid Testing Serology Covid Testing is a consulting group, distributor, and executor of advanced testing that specializes in bringing new health and wellness solutions and technologies to market. With over 20 years of experience, relationships, and well-established partnerships, we participate in implementing innovative technologies within our network of clinics in addition to bringing full-service testing services to businesses, schools, and events Nationwide. Serology Covid Testing is dedicated to meeting the urgent need for COVID-19 testing by utilizing cutting-edge technology, FDA or EUA approved assays, and highly trained laboratory professionals to deliver rapid results of unwavering quality. To learn more, visit: https://www.serology-testing.com/ About G Medical Innovations G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease and diabetes. The Company’s current product lines consist of its Prizma medical device (or Prizma), a clinical grade device that can transform almost any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous, and real time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services. Visit https://gmedinnovations.com/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, G Medical is using forward-looking statements when it discusses the agreement with Serology Covid Testing, providing end-to-end testing services including setup; certified medical staff; testing kits, supplies and necessary personal protective equipment; and an online patient portal to easily administer tests and provide digital certified lab results, the number of COVID-19 testing to be conducted and the timing thereof, and anticipated gross revenue. Because such statements deal with future events and are based on G Medical’s and McDade Products’ current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of G Medical and McDade Products could differ materially from those described in or implied by the statements in this press release. The forward looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in G Medical’s prospectus filed pursuant to Rule 424(b)(4), filed with the Securities and Exchange Commission (“SEC”) on June 28, 2021, and in any subsequent filings with the SEC. Except as otherwise required by law, the companies undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. G Medical and McDade Products are not responsible for the contents of third-party websites. INVESTOR RELATIONS AT GMEDICAL CONTACT: G Medical Innovations Kobi Ben-Efraim, CFO +972 8-958-4777 service@gmedinnovations.com SEROLOGY COVID TESTING CONTACT: Serology Covid Testing Andrew Benavente +1 310-747-5473 Andrew.m@Serology-Testing.com Contact Details Kobi Ben-Efraim, CFO +972 8-958-4777 service@gmedinnovations.com Company Website https://gmedinnovations.com/

January 25, 2022 04:03 AM Eastern Standard Time

Article thumbnail News Release

Winners of VinFuture's $4.5m global sci-tech prizes announced

Vingroup

The VinFuture Prize is aligned with one or more of the UN’s Sustainable Development Goals (SDGs) and is grounded in recognising proven, real-life impact Winners demonstrated breakthrough innovations in science and technology focused on driving meaningful and scalable change through improvements in health, prosperity, productivity, equity, and sustainability Recipients were selected from nearly 600 nominations across 60 countries HANOI, VIETNAM - Media OutReach - 21 January 2022 - The inaugural VinFuture Award Ceremony honors inventors of core mRNA vaccine technology; metal-organic frameworks (MOFs); flexible semiconductors with the sensing properties of human skin; and tenofovir gel for the prevention of HIV. These projects are exceptional scientific accomplishments that will positively impact the lives of billions of people on Earth in the present and future. Professor Katalin Kariko (third from right), Professor Pieter Cullis and Professor Drew Weissman (first and second from left) win VinFuture Grand Prize Honouring exceptional minds whose research and technological innovations will improve quality of life and ensure sustainable living for future generations, The VinFuture Prize was launched on International Solidarity Day 2020 and is uniquely aligned with one or more of the UN Sustainable Development Goals (SDGs). The award programme is part of the VinFuture Foundation, an independent, not-for-profit set up by Mr. Phạm Nhật Vượng, the first Vietnamese billionaire and Founder and Chairman of the largest Vietnamese conglomerate, Vingroup Corporate, together with his wife, Mrs. Phạm Thu Hương, to create meaningful change in the everyday lives of millions by recognising and rewarding transformative innovation in sci-tech. Attracting almost 600 nominations across 60 countries in its inaugural year, the Prize represents the best in science and technological breakthroughs in these fields. Of these nominations, nearly 100 came from the world’s top 2% most-cited scientists, many of whom are themselves laureates of distinguished awards, such as the Nobel Prize, Breakthrough Prize and Tang Prize, among others. The Grand Prize, valued at US$3 million, is awarded to three scientists: Katalin Kariko (USA), Drew Weissman (USA) and Pieter Cullis (Canada) for their work on mRNA technology, which paved the way for effective COVID-19 vaccines. In their research, they were able to modify mRNA and encapsulate it in lipid nanoparticles, preventing the immune system from reacting to foreign mRNA entering the body and avoiding cytokine induction, toxicity, and off-target effects. Based on Kariko and Weissman’s discovery, and Cullis’s development of lipid nanoparticles, pharmaceutical companies like Pfizer-BioNTech and Moderna were able to produce effective COVID-19 vaccines in record time. Besides serving as a global line of defense against the increasing infections and deaths caused by the pandemic, mRNA technology also has the potential to generate vaccines against HIV, cancer, autoimmune diseases and genetic diseases, potentially saving the lives of billions of people in the future. In addition to the Grand Prize, three Special Prizes, each valued at US$500,000, have been dedicated specifically for female innovators and to recognize innovations in emerging fields and in developing countries. The first Special Prize, dedicated to “Innovators with Outstanding Achievements in Emerging Fields”, is awarded to Professor Omar Yaghi (USA) for his work on discovering metal-organic frameworks (MOFs). MOFs are a new class of materials formed as networks of charged molecules linked to metal ions, with permanent porosity with high surface area and impressive stability. With tuneable pore sizes that enable the absorption and storage of gas and water molecules, MOFs provide solutions for the capture, storage, separation, and chemical manipulation of different types of gases and particles, and have the potential to create a cleaner environment and cleaner air, energy, and water sources. In particular, Professor Yaghi’s MOF water harvester has been proven to have the potential to generate clean water at any time, in any place. If successfully implemented, MOFs can improve the lives of millions of people in regions that lack access to clean water, helping increase water independence and increase quality of life. The second Special Prize, dedicated to “Female Innovators”, is awarded to Professor Zhenan Bao (USA) for her work on developing flexible electronics with the sensing properties of human skin. The electronics are made from a type of flexible molecular semiconductor material that has self-healing and biodegradable properties, allowing electronics to be integrated seamlessly into the human body. They have great potential in medical diagnosis and smart healthcare and can also be applied to wearable and implantable electronic devices, enhancing the quality of life of millions of people with disability and sparking future medical breakthroughs. Professors Salim Abdool Karim (second from right) and Professor Quarraisha Abdool Karim (second from left) win VinFuture Special Prize The Special Prize, for “Innovators from Developing Countries”, is awarded to Professors Salim Abdool Karim and Professor Quarraisha Abdool Karim from South Africa for their research on effective HIV prevention. With extensive experience in the field of epidemiology, the two scientists developed a tenofovir-based gel that prevents sexual transmission of HIV, laying the foundation for the pre-exposure prophylaxis (PrEP) method of preventing HIV. Salim Abdool Karim and Quarraisha Abdool Karim also created an oral medicine to create an HIV prevention strategy across the world, including for women and infants. The Karims’ research was recognized by UNAIDS and WHO as a pivotal scientific breakthrough, with significant impact on the prevention of an epidemic in the African continent and the world. Speaking about the results of the inaugural season of the VinFuture Prize, Professor Sir Richard Friend, VinFuture Prize Council Chair, stated: “The VinFuture Prize 2021 recognizes truly outstanding scientific work that has made and will make, a positive impact on the lives of millions, or even billions, of people around the world. The winners have brought new solutions for some of the most significant challenges that humanity is facing, such as infectious diseases and meeting the urgent need for zero carbon energy. The VinFuture Prize celebrates the power of science and technology to solve global problems.” On behalf of the Prize Laureates, Professor Katalin Kariko shared: “It is an incredible honor to learn that the Prize council selected me, together with my fellow scientists Drew Weissman and Pieter Cullis, to receive the inaugural VinFuture Grand Prize. We, as scientists, work at the bench in the laboratory, performing experiments day-after-day and hope that one day – maybe in our lifetime – we can witness that the advancements we made will be beneficial for the common good. We are all relieved and thrilled that our scientific discoveries laid the foundation for the development of the mRNA vaccines. It is also important to note that the vaccines were developed based on a century of scientific and technological progress and recent discoveries by hundreds of thousands of scientists, doctors, engineers and experts who advanced the knowledge of their respected fields, and the combination of that work led to the creation of these very effective and safe mRNA vaccines. We hope that our scientific adventure will also inspire the next generation of researchers and doctors, and that their contributions will advance our scientific knowledge on a higher level leading to the treatment of patients with unmet medical needs.” The first VinFuture Award Ceremony was broadcasted live on major communication channels across the world, with the appearance of Mr. Pham Minh Chinh, Prime Minister of Vietnam, leaders of domestic ministries and agencies, global ambassadors, industry leaders, and in particular, eminent international scientists. The Award Ceremony signals the end of the first season of the VinFuture Prize, with results far exceeding the expectations of the Prize Council in terms of both quantity, quality, and practical application potential of the nominations. The early success of the Prize lays the foundation for broadening the Prize’s impact in coming years, recognising scientists who seek and deliver solutions to humanity’s problems, contributing to creating a better life for everyone, and building a sustainable environment for future generations. Officially starting the second season of the VinFuture Prize The second cycle of the VinFuture Prize has now started, immediately following the conclusion of the inaugural VinFuture Award Ceremony. The VinFuture Foundation will open the nomination portal from February 15 running until June 3, 2022. Contact Details Vingroup Media Contact v.nammh@vingroup.net

January 20, 2022 08:26 PM Eastern Standard Time

Image
Article thumbnail News Release

The V Foundation for Cancer Research Receives $1 Million Gift

Advisors Excel

Pediatric cancer research recently received a million dollar infusion during an Advisors Excel training event. The V Foundation for Cancer Research will administer the funds through an open grant process. The V Foundation for Cancer Research was founded by ESPN and legendary basketball coach Jim Valvano with one goal in mind: to achieve Victory Over Cancer®. Since 1993, the V Foundation has awarded nearly $290 million in cancer research grants nationwide. It has become one of the premier supporters of cutting-edge cancer research. “Advisors Excel headed by Cody Foster and David Callanan, gave us at The V Foundation a golden opportunity to help youngsters in their battle vs. cancer,” said Dick Vitale, legendary sports commentator. “They blew us away with their generosity from their annual event by donating an incredible 1 million dollars that will go for pediatric cancer research through The V Foundation. I simply say the clients and staff of Advisors Excel are awesome baby with a capital A.” Advisors Excel raised funds in conjunction with more than 500 of the nation’s top financial professionals attending a three-day training event in Orlando. Each year, the company hosts the event, including an opportunity to raise money for a worthy cause. Since 2008, Advisors Excel and its affiliated independent financial professionals have raised approximately $6.3 million to help incredible nonprofits and organizations around the country. Private funding of pediatric research is critical to saving the lives of children with cancer. The disease is the leading cause of non-accidental deaths among American children. Government funding for pediatric research is minimal, and without funding, better tests and treatments cannot be developed. About 15,000 kids (infant to 19) are diagnosed with cancer every year. There have been great strides against the disease – the death rate for pediatric leukemia has declined by 70% over the last 45 years. The goal is to grow that number even more and to make those same strides against other cancers. For more information about the V Foundation, visit www.v.org. ### About Advisors Excel: Advisors Excel, founded in 2005, has redefined the role a marketing organization can play in supporting independent financial advisors. Their growth has been unparalleled in the industry and is achieved by working with a smaller group of select advisors. With a focus on making good advisors great business owners, Advisors Excel has revolutionized how financial professionals build and operate their businesses. In 2021, the 500 advisors working with Advisors Excel did over $8.9 billion in annuity, Medicare, and life insurance production. Their affiliated Registered Investment Advisory Firm, AE Wealth Management, currently manages over $18.8 billion and has been named one of the fastest-growing RIAs in the country. Contact Details Advisors Excel Tracey Stratton, Public Relations Manager +1 866-363-9595 tracey.stratton@advisorsexcel.com Company Website https://advisorsexcel.com

January 20, 2022 01:00 PM Eastern Standard Time

Image
1 ... 162163164165166 ... 215